Fundraising Fox
CellCentric
58 employees on LinkedIn · 10 known investors
Find your way into CellCentric
Sign up to see every warm intro you have to CellCentric
- Paths you didn't know you had: your email and LinkedIn already hold routes to the CellCentric team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
CellCentric develops inobrodib, a small-molecule oral p300/CBP inhibitor intended to treat multiple myeloma and other cancers. The company focuses on cell fate control mechanisms to identify novel targets for cancer treatments and works with scientific and clinical centers of excellence.
Founders & leadership
Investors · 10
How we know: Avego BioScience Capital's portfolio page · Not right? Tell us
How we know: Future Planet Capital's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: HBM Healthcare Investments's portfolio page · Not right? Tell us
How we know: HBM Partners's portfolio page · Not right? Tell us
How we know: Sofinnova Partners's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: open dataset · investor-profiles · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: funding news · Not right? Tell us
Funding
SEC filings, press & company announcements$440M disclosed across 2 rounds · 2026
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does CellCentric do?
- CellCentric develops inobrodib, a small-molecule oral p300/CBP inhibitor intended to treat multiple myeloma and other cancers. The company focuses on cell fate control mechanisms to identify novel targets for cancer treatments and works with scientific and clinical centers of excellence.
- Who founded CellCentric?
- CellCentric was founded by Azim Surani.
- Who are CellCentric's investors?
- CellCentric's investors include Avego BioScience Capital, Future Planet Capital, HBM Healthcare Investments, HBM Partners, RA Capital, Sofinnova Partners, BrightEdge, Forbion and 2 more.
- How much funding has CellCentric raised?
- CellCentric has disclosed $440M raised across 2 rounds.